Allie LogoA Search Service for Abbreviation / Long Form

■略語／展開語 : EVL／everolimus

関連PubMed/MEDLINE情報

合計出現文献数:

105

表示設定

略語:

EVL

(

>>共起略語

)

展開形:

everolimus

(免疫抑制薬;mTOR阻害作用) エベロリムス

EVL (104)回

evl (1)回

everolimus (86)回

Everolimus (19)回

EVL / everolimus (85)回

EVL / Everolimus (19)回

evl / everolimus (1)回

No.
発表年
題目
共起略語

1

2025

CI, CNIs, OR, eGFR

2

2024

Advances in understanding and managing pediatric heart failure and transplant.
HT, MMF, PHTS, RCT, SGLT2, TAC

3

2024

Effects of two immunosuppression regimens on T-lymphocyte subsets in elderly kidney transplant recipients.
MPS, rATG

4

2024

Safety and Efficacy of Mycophenolate Mofetil Associated With Tacrolimus for Kidney-pancreas and Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomized Studies.
AZA, CMV, EC-MPS, MAN, MMF, MZR, SRL, TAC

5

2023

Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi.
AmB, CBM, ITC, POS, VRC

6

2023

Analytical Performance of the New Siemens Affinity Chrome-Mediated Immunoassay Everolimus Assay and Its Interchangeability With the Thermo Quantitative Microsphere System for Routine Therapeutic Drug Monitoring of Patients After Solid Organ Transplantation.
ACMIA, LOQ, QC, QMS

7

2023

Assessment of the adverse effects of sirolimus versus everolimus in pediatric heart transplant recipients.
AEs, PSIs, SRL, eGFR

8

2023

Everolimus prevents doxorubicin-induced apoptosis in H9c2 cardiomyocytes but not in MCF-7 cancer cells: Cardioprotective roles of autophagy, mitophagy, and AKT.
Akt, DOX, mTOR

9

2023

Interactions between antifungals and everolimus against Cryptococcus neoformans.
AmB, CLSI, FICI, FLU, ITR, MICs, POS, VOR

10

2023

Prevalence and clinical characteristics of oral lesions in heart transplant patients induced by sirolimus and everolimus: a systematic review and meta-analysis on a global scale.
SRL

11

2023

The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score.
ACR, AMR, CAV, CKD, CMV, HT, LD-TAC, MATE, MMF, PTLD, RCT, TAC, eGFR

12

2023

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor-free, Belatacept Plus Everolimus-based Immunosuppression.
BELA, ITT, MMF, TAC

13

2022

Endogenous stimulus-responsive nitric oxide releasing bioactive liposome for a multilayered drug-eluting balloon.
DEB, ECs, EVL-NO-Lipo, NO, NOA, PCI, PVP, SMCs

14

2022

Evaluation of factors influencing the ratio of the trough blood concentration to dose level of everolimus in Japanese kidney transplant recipients.
CNI, ESRD, TAC

15

2022

In Vitro Interactions of Antifungal Agents and Everolimus Against Aspergillus Species.
AmB, ITC, POS, TOR, VRC, mTOR

16

2022

Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
CAV, HT, IVUS, TAC

17

2022

New-Onset Diabetes Mellitus in Post-renal Transplant Patients on Tacrolimus and Mycophenolate: A Systematic Review.
CYC, PTDM, TAC

18

2022

Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors.
BMI, FLD, LT

19

2022

The impact of mTOR inhibitors in the regression of left ventricular hypertrophy in elderly kidney transplant recipients.
ECHO, LVH, mTORi

20

2021

A Multilayer Functionalized Drug-Eluting Balloon for Treatment of Coronary Artery Disease.
DEBs, HCASMCs, PCI

Rows per page:

1–20 of 100